MedTrace Logo

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

NCT01082250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2011-09-08

No results posted yet for this study

Summary

A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl

Conditions

Interventions

DRUG

Lurasidone HCl

120mg dose. 3-way cross-over for 21 days

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Lev Gertsik, MD · California Clinical Trials (CCT)

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082250 on ClinicalTrials.gov